This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

This study has been terminated.
Information provided by:
Sumitomo Dainippon Pharma Co., Ltd. Identifier:
First received: February 1, 2006
Last updated: August 9, 2010
Last verified: August 2010
The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.

Condition Intervention Phase
Small-cell Lung Cancer Drug: Amrubicin Hydrochloride Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Sumitomo Dainippon Pharma Co., Ltd.:

Primary Outcome Measures:
  • Overall survival

Secondary Outcome Measures:
  • Time to progression
  • Objective tumor response
  • Quality of Life (QOL: EuroQOL, FACT-L-LCS)
  • Frequency and severity of adverse events

Estimated Enrollment: 130
Study Start Date: April 2006

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Extensive-disease small-cell lung cancer
  • Aged 70 years or older
  • Performance status of 0-2
  • No prior chemotherapy

Exclusion Criteria:

  • Prior therapy for primary lesion
  • Pneumonitis and/or pulmonary fibrosis
  • Active concomitant malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00286169

Chubu Region Site
Chubu, Japan
Chugoku Region Site
Chugoku, Japan
Hokkaido Region Site
Hokkaido, Japan
Kanto Region Site
Kanto, Japan
Kinki Region Site
Kinki, Japan
Kyushu Region Site
Kyushu, Japan
Shikoku Region Site
Shikoku, Japan
Tohoku Region Site
Tohoku, Japan
Sponsors and Collaborators
Sumitomo Dainippon Pharma Co., Ltd.
Study Director: Drug Development Division Dainippon Sumitomo Pharma Co., Ltd.
  More Information Identifier: NCT00286169     History of Changes
Other Study ID Numbers: D0702002
Study First Received: February 1, 2006
Last Updated: August 9, 2010

Keywords provided by Sumitomo Dainippon Pharma Co., Ltd.:
Extensive-disease small-cell lung cancer (ED-SCLC)

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents processed this record on September 20, 2017